UBS Stock Recent News

Brussels, September 27, 2024, 08:30 CEST - Regulated information In line with Belgian transparency legislation (Law of May 2, 2007), UBS Group AG recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%.  The notification, dated September 24, 2024, contains the following information: Reason for the notification:  Acquisition or disposal of voting securities or voting rights Acquisition or disposal of financial instruments that are treated as voting securities Downward crossing of the lowest threshold Notified by: A parent undertaking or a controlling person Date on which the threshold is crossed: September 18, 2024 Threshold of direct voting rights crossed: 3% downwards Denominator: 105,876,416  Additional information: The disclosure obligation arose due to the total indirect holdings of UBS Group AG in voting rights of Solvay SA, held directly by controlled undertakings falling below 3% on 18 September 2024.

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that its SmartGateway screening solution was selected to secure UBS Arena in New York.

IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Aziz Mottiwala, Chief Commercial Officer, will participate in a virtual fireside chat at the UBS Virtual Ophthalmology Day 2024 taking place on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET.

BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in the UBS Virtual Opthalmology Day 2024:

WALTHAM, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the UBS Virtual Ophthalmology Day on Wednesday, October 2, 2024, at 8:30 a.m. ET.

Investment analysts at UBS have warned that weakening sales growth at LVMH is posing a risk to margins and causing a delay to a potential recovery phase for the global luxury bellwether. UBS analyst Zuzanna Pusz expects to see decelerating organic sales growth (OSG) in the third quarter, despite an easier comparable basis.

Swiss financial market regulator FINMA ordered an audit into Credit Suisse's handling of events leading to its demise in 2023, when the bank was acquired by its longtime rival UBS , Swiss newspaper SonntagsZeitung reported on Sunday.

John Lovallo, UBS homebuilders analyst, joins 'The Exchange' to discuss why he is bullish on builders, how lower interest rates will affect the stocks and housing market, and more.

Ceres Power Holdings PLC (LSE:CWR, OTC:CPWHF)  updated its 2024 guidance in July, so next week's trading update might just be a reiteration of that suggests UBS especially with a new finance head joining in October. BS said it would like confirmation of the cash runway would be welcome and how far this will take it towards EBITDA break even.

Nearly a quarter of Swiss industrial companies are unhappy with the service from UBS , notably in lending, since its 2023 Credit Suisse takeover, a survey found, in a blow to the bank's efforts to show it is not abusing its market dominance.